About: uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Sector: Healthcare
Industry: Biotechnology
Latest price: $23.06 (+1.14%)
QURE NASDAQ Uniqure NV
Uniqure NV share price
QURE price activity
Último preço
$ 23,060
Variação (24h)
0,26 USD (1,14%)
Volume
2.78M
Volume (média 4 sem.)
-
Abertura
$ 23,02
Variação do dia
$ 21,20 - $ 23,84
Fechamento anterior
$ 22,80
Último negócio
06 Oct, 8:20 pm GMT+0
Atrasado
06 Oct, 8:20 pm GMT+0
QURE price performance
Atrasado
06 Oct, 8:20 pm GMT+0
quote.marketSignals